Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?

Detalhes bibliográficos
Autor(a) principal: Tokgoz,Husnu
Data de Publicação: 2007
Outros Autores: Turkolmez,Kadir, Resorlu,Berkan, Kose,Kenan, Tulunay,Ozden, Beduk,Yasar
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000600005
Resumo: OBJECTIVE: Compare clinical outcomes in patients having urothelial tumors invading less than one half of the depth of bladder muscle and greater than one half of bladder muscle and, to determine various clinical variables as predictive factors for survival. MATERIALS AND METHODS: According to our inclusion criteria, 57 patients among cases with T2 bladder tumor were selected. Thirty-five patients (61.4 %) had pT2a (Group-1) and 22 patients (38.6%) had pT2b (Group-2) muscle invasive tumors. Mean follow up time was 7.3 years for Group-1, and 6.1 years for Group-2. Multivariate analysis was performed in order to identify possible correlation of clinical variables like age, gender, grade of primary tumor, appearance of local and/ or distant metastasis with patient outcome. RESULTS: Five year recurrence-free and overall survival rates were 69.1% and 44.3% for patients with pT2a tumor, whereas these ratios were 66.1% and 43%, respectively for patients with pT2b tumor (p = 0.896; p = 0.975). Mean overall and progression-free survival times were 87.7 ± 13.8 and 116 ± 13.12 months for Group-1, while they were 73.8 ± 13.7 and 88.85 ± 12.55 months for Group-2, respectively. On both univariate and multivariate analysis, age was noticed as an independent predictive factor for survival. CONCLUSIONS: The depth of muscle invasion in bladder tumors has no prognostic significance. Recurrence of the disease either locally or at distant sites dramatically shortens patients' life. Being older than 60 years old during the time of radical surgery, is also a bad prognostic factor for overall and progression-free survival.
id SBU-1_f8a36eb874f998a49cd52f1958cfe5c4
oai_identifier_str oai:scielo:S1677-55382007000600005
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?bladder neoplasmsTNM stagingneoplasm stagingsurvivalOBJECTIVE: Compare clinical outcomes in patients having urothelial tumors invading less than one half of the depth of bladder muscle and greater than one half of bladder muscle and, to determine various clinical variables as predictive factors for survival. MATERIALS AND METHODS: According to our inclusion criteria, 57 patients among cases with T2 bladder tumor were selected. Thirty-five patients (61.4 %) had pT2a (Group-1) and 22 patients (38.6%) had pT2b (Group-2) muscle invasive tumors. Mean follow up time was 7.3 years for Group-1, and 6.1 years for Group-2. Multivariate analysis was performed in order to identify possible correlation of clinical variables like age, gender, grade of primary tumor, appearance of local and/ or distant metastasis with patient outcome. RESULTS: Five year recurrence-free and overall survival rates were 69.1% and 44.3% for patients with pT2a tumor, whereas these ratios were 66.1% and 43%, respectively for patients with pT2b tumor (p = 0.896; p = 0.975). Mean overall and progression-free survival times were 87.7 ± 13.8 and 116 ± 13.12 months for Group-1, while they were 73.8 ± 13.7 and 88.85 ± 12.55 months for Group-2, respectively. On both univariate and multivariate analysis, age was noticed as an independent predictive factor for survival. CONCLUSIONS: The depth of muscle invasion in bladder tumors has no prognostic significance. Recurrence of the disease either locally or at distant sites dramatically shortens patients' life. Being older than 60 years old during the time of radical surgery, is also a bad prognostic factor for overall and progression-free survival.Sociedade Brasileira de Urologia2007-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000600005International braz j urol v.33 n.6 2007reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-55382007000600005info:eu-repo/semantics/openAccessTokgoz,HusnuTurkolmez,KadirResorlu,BerkanKose,KenanTulunay,OzdenBeduk,Yasareng2008-05-21T00:00:00Zoai:scielo:S1677-55382007000600005Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2008-05-21T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
title Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
spellingShingle Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
Tokgoz,Husnu
bladder neoplasms
TNM staging
neoplasm staging
survival
title_short Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
title_full Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
title_fullStr Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
title_full_unstemmed Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
title_sort Pathological staging of muscle invasive bladder cancer: is substaging of pT2 tumors really necessary?
author Tokgoz,Husnu
author_facet Tokgoz,Husnu
Turkolmez,Kadir
Resorlu,Berkan
Kose,Kenan
Tulunay,Ozden
Beduk,Yasar
author_role author
author2 Turkolmez,Kadir
Resorlu,Berkan
Kose,Kenan
Tulunay,Ozden
Beduk,Yasar
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Tokgoz,Husnu
Turkolmez,Kadir
Resorlu,Berkan
Kose,Kenan
Tulunay,Ozden
Beduk,Yasar
dc.subject.por.fl_str_mv bladder neoplasms
TNM staging
neoplasm staging
survival
topic bladder neoplasms
TNM staging
neoplasm staging
survival
description OBJECTIVE: Compare clinical outcomes in patients having urothelial tumors invading less than one half of the depth of bladder muscle and greater than one half of bladder muscle and, to determine various clinical variables as predictive factors for survival. MATERIALS AND METHODS: According to our inclusion criteria, 57 patients among cases with T2 bladder tumor were selected. Thirty-five patients (61.4 %) had pT2a (Group-1) and 22 patients (38.6%) had pT2b (Group-2) muscle invasive tumors. Mean follow up time was 7.3 years for Group-1, and 6.1 years for Group-2. Multivariate analysis was performed in order to identify possible correlation of clinical variables like age, gender, grade of primary tumor, appearance of local and/ or distant metastasis with patient outcome. RESULTS: Five year recurrence-free and overall survival rates were 69.1% and 44.3% for patients with pT2a tumor, whereas these ratios were 66.1% and 43%, respectively for patients with pT2b tumor (p = 0.896; p = 0.975). Mean overall and progression-free survival times were 87.7 ± 13.8 and 116 ± 13.12 months for Group-1, while they were 73.8 ± 13.7 and 88.85 ± 12.55 months for Group-2, respectively. On both univariate and multivariate analysis, age was noticed as an independent predictive factor for survival. CONCLUSIONS: The depth of muscle invasion in bladder tumors has no prognostic significance. Recurrence of the disease either locally or at distant sites dramatically shortens patients' life. Being older than 60 years old during the time of radical surgery, is also a bad prognostic factor for overall and progression-free survival.
publishDate 2007
dc.date.none.fl_str_mv 2007-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000600005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382007000600005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1677-55382007000600005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.33 n.6 2007
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318070532931584